Albireo Pharma, Inc. (NASDAQ:ALBO) Forecasted to Post Q2 2022 Earnings of ($1.95) Per Share

Albireo Pharma, Inc. (NASDAQ:ALBOGet Rating) – Equities research analysts at Jefferies Financial Group raised their Q2 2022 earnings per share (EPS) estimates for shares of Albireo Pharma in a research note issued on Monday, May 16th. Jefferies Financial Group analyst E. Yang now expects that the biopharmaceutical company will post earnings of ($1.95) per share for the quarter, up from their prior estimate of ($1.98). Jefferies Financial Group also issued estimates for Albireo Pharma’s Q3 2022 earnings at ($1.96) EPS, Q4 2022 earnings at ($2.03) EPS, FY2022 earnings at ($8.13) EPS, FY2023 earnings at ($5.51) EPS, FY2024 earnings at ($2.48) EPS, FY2025 earnings at $3.49 EPS and FY2026 earnings at $10.27 EPS.

Albireo Pharma (NASDAQ:ALBOGet Rating) last issued its quarterly earnings results on Monday, May 16th. The biopharmaceutical company reported ($2.19) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.02) by ($0.17). Albireo Pharma had a negative return on equity of 72.90% and a negative net margin of 72.02%. During the same quarter last year, the business earned ($2.29) EPS.

A number of other analysts also recently weighed in on ALBO. Wedbush restated a “buy” rating and issued a $72.00 price target on shares of Albireo Pharma in a research note on Tuesday. began coverage on shares of Albireo Pharma in a research note on Thursday, March 31st. They set a “hold” rating on the stock. Finally, Robert W. Baird reduced their price objective on shares of Albireo Pharma from $72.00 to $66.00 in a research note on Tuesday. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $62.00.

NASDAQ ALBO opened at $21.16 on Thursday. The stock has a market capitalization of $409.66 million, a price-to-earnings ratio of -12.02 and a beta of 0.95. The business’s 50 day moving average is $31.79 and its two-hundred day moving average is $28.66. Albireo Pharma has a 12-month low of $20.30 and a 12-month high of $37.86. The company has a current ratio of 5.93, a quick ratio of 5.93 and a debt-to-equity ratio of 0.06.

Several large investors have recently modified their holdings of ALBO. Endurant Capital Management LP increased its position in Albireo Pharma by 84.1% during the 1st quarter. Endurant Capital Management LP now owns 120,834 shares of the biopharmaceutical company’s stock worth $3,604,000 after purchasing an additional 55,196 shares in the last quarter. Invesco Ltd. acquired a new position in shares of Albireo Pharma in the first quarter valued at approximately $203,000. UBS Group AG lifted its stake in shares of Albireo Pharma by 166.4% during the first quarter. UBS Group AG now owns 41,298 shares of the biopharmaceutical company’s stock valued at $1,232,000 after buying an additional 25,796 shares during the period. Renaissance Technologies LLC acquired a new stake in Albireo Pharma during the first quarter worth approximately $286,000. Finally, Charles Schwab Investment Management Inc. grew its stake in Albireo Pharma by 0.8% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 46,147 shares of the biopharmaceutical company’s stock worth $1,377,000 after acquiring an additional 375 shares during the period. Institutional investors and hedge funds own 82.99% of the company’s stock.

In other Albireo Pharma news, CEO Ronald Harold Wilfred Cooper sold 907 shares of the company’s stock in a transaction on Friday, April 22nd. The stock was sold at an average price of $33.11, for a total value of $30,030.77. Following the sale, the chief executive officer now owns 56,082 shares of the company’s stock, valued at $1,856,875.02. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last quarter, insiders have sold 1,872 shares of company stock worth $61,139. 5.00% of the stock is owned by company insiders.

Albireo Pharma Company Profile (Get Rating)

Albireo Pharma, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. The company offers Bylvay for the treatment of progressive familial intrahepatic cholestasis, as well as in Phase III clinical trial for treating biliary atresia, alagille syndrome, and rare and life-threatening disorder to children; and Elobixibat for the treatment of chronic constipation and other functional diseases.

Read More

Earnings History and Estimates for Albireo Pharma (NASDAQ:ALBO)

Receive News & Ratings for Albireo Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albireo Pharma and related companies with's FREE daily email newsletter.